TY - JOUR T1 - Dose response of sodium glucose cotransporter-2 inhibitors in relation to urinary tract infections: a systematic review and network meta-analysis of randomized controlled trials JF - CMAJ Open JO - CMAJ SP - E594 LP - E602 DO - 10.9778/cmajo.20180111 VL - 6 IS - 4 AU - Jennifer R. Donnan AU - Catherine A. Grandy AU - Eugene Chibrikov AU - Carlo Marra PharmD AU - Kris Aubrey-Bassler AU - Karissa Johnston AU - Michelle Swab AU - Jenna Hache AU - Daniel Curnew AU - Hai Nguyen AU - John-Michael Gamble Y1 - 2018/10/01 UR - http://www.cmajopen.ca/content/6/4/E594.abstract N2 - Background: The sodium glucose cotransporter-2 (SGLT2) inhibitors are a novel group of drugs for treatment of type 2 diabetes mellitus. We investigated whether there is a dose–response relation between SGLT2 inhibitors and urinary tract infections (UTIs) in patients with type 2 diabetes, relative to other diabetes therapies or placebo.Methods: We conducted a systematic review and network meta-analysis of randomized controlled trials (RCTs) of SGLT2 inhibitors in patients with type 2 diabetes. We searched 6 databases and the reference lists of key papers. We included studies with placebo or active antidiabetic comparators that reported the outcome of UTI, and established thresholds for high and low doses of SGLT2 inhibitors. We used a random-effects model to estimate the pooled effect estimates and 95% credible intervals.Results: We screened 2418 citations and included 105 references for studies of 8 unique SGLT2 inhibitors, representing 60 082 individuals (with a total of 4348 UTIs). Most mixed-treatment comparisons showed no significant difference in risk of UTI, with the exception of high-dose dapagliflozin (≥ 10 mg) compared with placebo (odds ratio [OR] 1.30, 95% credible interval 1.09–1.57), with active comparators (OR 1.44, 95% credible interval 1.15–1.79), with empagliflozin at both low (OR 1.30, 95% credible interval 1.04–1.60) and high (OR 1.39, 95% credible interval 1.12–1.72) doses, and with low-dose ertugliflozin (OR 1.43, 95% credible interval 1.01–2.01). When the analysis was restricted to RCTs with a low risk of bias, the results were nonsignificant.Interpretation: Current RCT evidence does not suggest a dose–response relation between most SGLT2 inhibitors and UTIs, with the exception of dapagliflozin. Further research is needed to quantify the relation between SGLT2 inhibitors and more serious infections.Trial registration: PROSPERO registration no. CRD42016038715. ER -